Abstract
Coastal: A Phase 3 Study of the PI3Kδ Inhibitor Zandelisib with Rituximab (R) Versus Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have